March 27, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Nuvectis Pharma, Inc. Registration Statement on Form S-3 | |
| File No. 333-270657 |
Ladies and Gentlemen:
Nuvectis Pharma, Inc. (the “Company”) hereby requests, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 9:00 a.m. EST on March 29, 2023, or as soon thereafter as practicable.
Please contact Matt Mamak of Alston & Bird LLP, the Company’s counsel, at (212) 210-1256, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
| Nuvectis Pharma, Inc. | ||
| By: | /s/ Ron Bentsur | |
| Name: Ron Bentsur | ||
| Title: Chairman, Chief Executive Officer and President | ||